Thanks vii

Presentation of the Authors ix

Preface xi

Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products, O.J.E.C., 22.1.2000, L 18/1 ff. 1

Practical Commentary on Regulation No. 141/2000 8

Geneviève Michaux, Covington & Burling LLP

A. Designation as Orphan Medicinal Product 9
1. Designation Criteria 10
a) Condition 10
Condition v. Disease 10
Medical Plausibility 10
Orphan Indication 11
b) Prevalence Criterion or Financial Criterion 11
Prevalence Criterion 11
Financial Criterion 11
c) No Alternative Methods or Significant Therapeutic Benefit 12
No Alternative Methods 12
Significant Therapeutic Benefit 12
2. Procedure for Orphan Designation (Art.5 (1)) 14
a) Who Can Submit an Application for Orphan Designation? 14
b) When to Submit the Application? 14
c) Designation Procedure 14
d) The Community Register of Orphan Medicinal Products 15
e) Annual Reports 15
f) Several Sponsors? 15
g) Parallel Procedure with FDA 15
h) Belgium 16
3. Transfer of Orphan Designation (Art.5 (11)) 16
4. Removal from the Registry of Orphan Medicinal Products(Art.5 (12)) 16
B. Marketing Authorisation (Art.7) 17
1. Use of the Centralised Procedure 17
2. MA for Orphan Indication(s) Only 17
3. Review of the Designation Criteria 18
4. Accelerated Review and Approval 19
C. Incentives 19
1. Market Exclusivity (Art.8) 20
a) Market Exclusivity Period 20
b) Reduction of Market Exclusivity (Art.8 (2)) 20
c) Derogations of Market Exclusivity (Art.8(3)) 21
d) Extension of Market Exclusivity 23
e) Specific Issues with Regard to Market Exclusivity 25

2. Other Incentives . . . 26
a) Reduction of Fees . . . 26
b) Incentives from Member States (Art.9) . . . 26
Belgium . . . 26
c) Action Plans . . . 27
D. Pricing and Reimbursement . . . 28
1. European Union . . . 28
2. Belgium . . . 29
a) Pricing . . . 29
b) Reimbursement . . . 29
E. The Future . . . 30

Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community Procedures for the Authorisation and Supervision of Medicinal Products for Human and Veterinary Use and establishing a European Medicines Agency, O.J.E.C., 30.4.2004, L 136/1 ff. (consolidated version) . . . 32

Practical Commentary on Regulation No. 726/2004 . . . 78

Thibaut D'hulst, Peter L'Ecluse, Catherine Longeval and Koen T'Syen, Van Bael & Bellis

A. Introduction . . . 78
B. Scope . . . 79
1. Mandatory Scope . . . 79
a) Human or Veterinary Medicinal Products derived from Biotechnology . . . 79
b) Advanced Therapy Medicinal Products for Human Use . . . 79
c) Performance Enhancers for Veterinary Use . . . 80
d) Human Medicinal Products containing a new Active Substance for the Treatment of certain Specific Diseases . . . 80
e) Orphan Medicinal Products for Human Use . . . 80
2. Optional Scope . . . 81
3. Generic Medicinal Products . . . 81
C. Authorisation Procedure . . . 81
1. Medicinal Products for Human Use . . . 81
a) Pre-Submission . . . 81
b) Submission of the MAA . . . 82
c) Validation and Evaluation of the MAA . . . 83
d) The Marketing Authorisation . . . 85
2. Medicinal Products for Veterinary Use . . . 86
D. Supervision . . . 86
1. Medicinal Products for Human Use . . . 87
a) The Supervisory Authorities . . . 87
b) Tasks . . . 87
c) Variations . . . 87
2. Medicinal Products for Veterinary Use . . . 88
E. Pharmacovigilance . . . 88
1. Medicinal Products for Human Use . . . 88
a) The Marketing Authorisation Holder . . . 88

b) The Member States 89
c) EMEA 89
d) The Commission 90
e) The Commission's Pharmaceutical Package of December 2008 90
2. Medicinal Products for Veterinary Use 91
F. EMEA 91

Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004, O.J.E.C., 27.12.2006, L 378/1 ff. (consolidated version) 92

Practical Commentary on Regulation No. 1901/2006 121

Geneviève Michaux, Covington & Burling LLP

A. Scope of Application of the Paediatric Obligation 122
1. Mandatory Paediatric Obligation 122
2. Optional Paediatric Obligation (Art.30) 123
3. Exemptions (Art.9) 123
4. Meaning of Articles 7 and 8 124
a) "Medicinal Product" 124
b) Article 7 (New Product) 125
c) Article 8 (On-Patent Approved Products) 125
B. Paediatric Investigation Plan 126
1. Definition of a PIP 126
2. Content of the PIP 126
a) Paediatric Population 126
b) Indication, Condition, or Mechanism of Action? 126
c) All Paediatric Studies? 127
C. Waivers and Deferrals 127
1. Waivers (Art.11 to 14) 127
2. Deferrals (Art. 20 and 21) 128
D. Paediatric Procedure 129
1. Time of Submission of the PIP Proposal (Art.16) 129
2. Approval of the PIP Proposal and Waivers/Deferrals (Art. 15 to 19 and 25) 129
3. Modification of the PIP (Art.22) 131
4. Withdrawal of the PIP? 131
E. Compliance Check (Art.23 and 24) 131
1. By What Authority? 131
2. What is to be Checked? 132
3. When? 132
4. No Compliance Check 133
5. Statement of Compliance (Art.28 (3)) 133
F. Impact of the Paediatric Regime on the Regulatory Approval Procedure 133
1. Invalidity of the Regulatory Application 133
2. Use of the Procedures (Art.28 and 29) 133
3. Compliance Check by the Regulatory Authority 134

4. Content of the MA and Product Information (Art.28(2) and (3)) 134
5. PUMA (Art.30 and 31) 134
G. Paediatric Rewards 135
1. Types of Rewards (Art.36 to 39) 135
2. Substantive Requirements 135
a) Overview 135
b) Approval of the Product in all EU Member States (Art.36(3)) 136
c) Compliance with the Agreed PIP (Art.36(1)) 137
d) Amendment to the SmPC (Art.28 (1) and 36(1)) 137
e) Completion of Significant Studies after 26 January 2007 (Art.45 (3)) 137
f) No Orphan Designation (Art.36(4)) 138
g) No +1 Year Data Exclusivity (Art.36(5)) 138
h) No Previous SPC Extension (Art.52 (9)) 139
3. Procedural Requirements 139
a) SPC Extension 139
b) Market Exclusivity Extension 141
4. Main Issues 141
a) SPC with a "0" Term or a Negative Term 141
b) Multiple SPCs 142
c) Orphan Products 143
H. Other Obligations 143
1. Paediatric Symbol (Art.32) 143
2. Increased Pharmacovigilance Obligations (Art.34) 143
3. Obligation to Market and to continue Marketing (Art.33 and 35) 144
4. Transparency 144
a) Submission of Results of Paediatric Studies (Art.46) 144
b) Insertion of Paediatric Clinical Trials in EudraCT (Art.41 (1)) 144
c) Publication of Results (Art.41 (2)) 145
I. Collection of Past Paediatric Data 145
1. Mandatory Submission by MAHs (Art.45) 145
2. Collection by the Authorities (Art.42) 145
J. Sanctions (Art.49 and 50) 146

Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No. 726/2004, O.J.E.C., 10.12.2007, L 324/21 ff. (consolidated version) 147

Practical Commentary on Regulation No. 1394/2007 167

Marc Martens & Nicolas Carbonnelle, Bird & Bird

A. Introduction 167
B. History and Regulatory Context of the ATMP-Regulation 167
C. Advanced Therapy Medicinal Products 168
1. Birth of a New Category of Medicinal Products 168
2. Three Categories of Products 169
a) Gene Therapy Medicinal Products 169
b) Somatic Cell Therapy Medicinal Products 169

c) Tissue-Engineered Products . . . 170
d) Combined ATMPs . . . 171
e) Classification Rules . . . 171
D. Donation, Procurement and Testing of Human Tissues and Cells intended for the Manufacture of ATMPs . . . 171
E. Marketing Authorisation for ATMPs . . . 172
F. Summary of Product Characteristics, Labelling and Package Leaflet . . . 172
G. Post-Authorisation Requirements . . . 172
1. Follow-Up of Efficacy and Risk Management . . . 173
2. Traceability . . . 173
H. Committee for Advanced Therapies (CAT) . . . 174
1. Role and Responsibilities . . . 174
2. Composition . . . 174
I. Incentives for Small and Medium Sized Enterprises . . . 175
J. Transitional Period . . . 175
K. Ethical Neutrality of the ATMP Regulation . . . 175
L. Belgian Regulation . . . 176
1. State of Implementation of the Directives . . . 176
2. Donation, Procurement and Testing of Human Tissue and Cells . . . 176
3. The New Belgian Legislation . . . 177
a) Current State of Play . . . 177
b) Four Types of Structures . . . 178
c) Performing R&D under the New Provisions . . . 178
M. Conclusion . . . 179

References and Sources . . . 179